Drug affordability review

The Prescription Drug Affordability Board (PDAB) has revised its affordability review schedule for 2024. In January, the board reviewed insulin products. In May through November, the board will review the prescription drugs listed in the revised table below. The affordability review drug reports will be posted with the agenda materials one week before the board meeting and also linked to the drug name below.

Written comments specific to drugs under review and submitted by the deadlines below will be included in the drug reports that are posted one week before the meeting. However, written comments specific to drugs under review may be submitted up until 72 hours before the November board meeting. To submit a comment for affordability review, complete and submit the public comment form.